Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer
December 14, 2022 02:00 ET
|
Ultimovacs ASA
First clinical trial based on Ultimovacs’ proprietary TET adjuvant platform technologyFirst clinical trial based on Ultimovacs’ proprietary TET adjuvant platform technology12 patients with prostate...
Ultimovacs ASA: Mandatory notification of trade by primary insider
November 29, 2022 11:00 ET
|
Ultimovacs ASA
Oslo, 29 November 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,500 shares in the company at an average price of...
Ultimovacs ASA: New share capital registered
November 21, 2022 01:00 ET
|
Ultimovacs ASA
Oslo, 21 November 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 16 November 2022 regarding the issuance of new shares in connection with the Company's employee incentive...
Ultimovacs ASA: Share capital increase related to exercise of options
November 16, 2022 05:56 ET
|
Ultimovacs ASA
Oslo, 16 November 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital, related to the exercise of options, by NOK 13,070 through the...
Ultimovacs ASA: Mandatory notification of trade by primary insider
November 10, 2022 11:00 ET
|
Ultimovacs ASA
Oslo, 10 November 2022, Radforsk Investeringstiftelse, a closely associated party of Jónas Einarsson, a primary insider and chair of the board of the Company, has today bought 5,250 shares in the...
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
November 10, 2022 02:00 ET
|
Ultimovacs ASA
Oslo, November 10, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its third quarter 2022 results today. Third Quarter...
Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation
November 03, 2022 03:00 ET
|
Ultimovacs ASA
Oslo, 3 November 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its third quarter 2022 results...
Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)
October 25, 2022 02:00 ET
|
Ultimovacs ASA
Fifth phase II trial assessing the impact of UV1 in various immunotherapy combinationsEnrollment of 138 patients at approximately all lung cancer centers in NorwayNon-small cell lung cancer is one of...
Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility
October 18, 2022 02:00 ET
|
Ultimovacs ASA
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Biomarker data support strong clinical responses from UV1 in combination...
Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma
October 05, 2022 13:26 ET
|
Ultimovacs ASA
Malignant melanoma patients treated with immunotherapy combination UV1 and pembrolizumab in phase I clinical trialConsistently high overall survival (OS) rate: 71% at three-year follow-up of patients...